Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Int J Infect Dis. 2023 Jul;132:50-63. doi: 10.1016/j.ijid.2023.04.392. Epub 2023 Apr 16.
To estimate the pooled proportion of extensively drug-resistant tuberculosis (XDR-TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) in patients with multidrug-resistant TB (MDR-TB).
We systematically searched articles from electronic databases: MEDLINE (PubMed), ScienceDirect, and Google Scholar. We also searched gray literature from the different literature sources main outcome of the review was either XDR-TB or pre-XDR-TB in patients with MDR-TB. We used the random-effects model, considering the substantial heterogeneity among studies. Heterogeneity was assessed by subgroup analyses. STATA version 14 was used for analysis.
A total of 64 studies that reported on 12,711 patients with MDR-TB from 22 countries were retrieved. The pooled proportion of pre-XDR-TB was 26% (95% confidence interval [CI]: 22-31%), whereas XDR-TB in MDR-TB cases was 9% (95% CI: 7-11%) in patients treated for MDR-TB. The pooled proportion of resistance to fluoroquinolones was 27% (95% CI: 22-33%) and second-line injectable drugs was 11% (95% CI: 9-13%). Whereas the pooled resistance proportions to bedaquiline, clofazimine, delamanid, and linezolid were 5% (95% CI: 1-8%), 4% (95% CI: 0-10%), 5% (95% CI; 2-8%), and 4% (95% CI: 2-10%), respectively.
The burden of pre-XDR-TB and XDR-TB in MDR-TB were considerable. The high burdens of pre-XDR-TB and XDR-TB in patients treated for MDR-TB suggests the need to strengthen TB programs and drug resistance surveillance.
估计耐多药结核病(MDR-TB)患者中广泛耐药结核病(XDR-TB)和耐多药前广泛耐药结核病(pre-XDR-TB)的总体比例。
我们系统地从电子数据库(MEDLINE(PubMed)、ScienceDirect 和 Google Scholar)中检索文章。我们还从不同文献来源中检索灰色文献,综述的主要结局是 MDR-TB 患者中的 XDR-TB 或 pre-XDR-TB。我们使用随机效应模型,考虑到研究之间存在很大的异质性。通过亚组分析评估异质性。使用 STATA 版本 14 进行分析。
共检索到来自 22 个国家的 64 项研究,共报告了 12711 例 MDR-TB 患者。耐多药前广泛耐药结核病的总体比例为 26%(95%置信区间 [CI]:22-31%),而接受 MDR-TB 治疗的患者中,XDR-TB 的比例为 9%(95% CI:7-11%)。氟喹诺酮类药物耐药的总体比例为 27%(95% CI:22-33%),二线注射类药物耐药的总体比例为 11%(95% CI:9-13%)。而贝达喹啉、氯法齐明、德拉马尼和利奈唑胺的耐药总体比例分别为 5%(95% CI:1-8%)、4%(95% CI:0-10%)、5%(95% CI:2-8%)和 4%(95% CI:2-10%)。
MDR-TB 中耐多药前广泛耐药结核病和 XDR-TB 的负担相当大。MDR-TB 患者中耐多药前广泛耐药结核病和 XDR-TB 的高负担表明需要加强结核病规划和耐药监测。